Janssen's Stelara Rejection At NICE Puts Innovation In The Spotlight
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen's Stelara has been blocked from the NHS by NICE because, although innovative, it is not the step change that the British reimbursement watchdog wants.